|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.92 USD | -0.92% |
|
+1.43% | -1.87% |
| 17/04 | Goldman Sachs Adjusts Incyte Price Target to $100 From $98, Maintains Neutral Rating | MT |
| 14/04 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- INCY Stock
- Consensus Incyte Corporation
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition